Cover Image
市場調查報告書

頭孢菌素劑的全球市場:2015-2019年

Global Cephalosporin Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 340622
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
頭孢菌素劑的全球市場:2015-2019年 Global Cephalosporin Drugs Market 2015-2019
出版日期: 2015年09月23日 內容資訊: 英文 100 Pages
簡介

全球頭孢菌素劑的市場預計從2014年到2019年將以3.21%的年複合成長率成長。

本報告提供全球頭孢菌素劑市場相關調查,提供您頭孢菌素的開發過程與作用機制,抗生劑利用原則,美國的相關法律,不同地區抗生劑利用趨勢,頭孢菌素劑的收益規模的變化與預測,世代·途徑相關趨勢,各地區的收益規模的變化與預測,市場成長的各種影響因素分析,競爭環境與市場佔有率,並彙整主要供應商簡介等資料。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商的提供產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 市場焦點

第5章 頭孢菌素概要

  • 簡介
  • 頭孢菌素的前導物質
  • 作用機制
  • 抗生素利用的原則
  • 臨床性利用
  • 流行病學

第6章 抗生素的消費:概要

  • 南美
  • 歐洲
  • 亞太地區

第7章 抗生素的利用相關法規:美國

第8章 市場環境

  • 市場概要
  • 市場規模·預測
  • 波特的五力分析

第9章 按市場分析:頭孢菌素世代

  • 第1代
  • 第2代
  • 第3代
  • 第4代
  • 第5代

第10章 市場分析:各途徑

  • 注射
  • 口服

第11章 地區分析

  • 全球頭孢菌素劑市場:各地區
  • 南北美洲
  • 歐洲
  • 亞太地區

第12章 市場成長因素

第13章 成長因素的影響

第14章 市場課題

第15章 成長推進因素·課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 市場佔有率分析
  • 其他的有力供應商

第18章 主要供應商分析

  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

第19章 附錄

第20章 關於Technavio

圖表

目錄
Product Code: IRTNTR7550

About cephalosporins

Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into "generations" by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.

Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Aspen Pharmacare
  • AstraZeneca
  • Aurobindo Pharma
  • Basilea Pharmaceuticals
  • Baxter
  • Biocon
  • Corden Pharma
  • Cornerstone Therapeutics
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Flynn Pharma
  • Hospira
  • Incepta Pharmaceuticals
  • Johnson & Johnson
  • Kyorin Pharmaceutical
  • Lupin Pharmaceuticals
  • Orchid Pharma
  • Par Pharmaceutical
  • Pernix Therapeutics
  • Sanofi
  • Shionogi
  • Sun Pharmaceutical
  • Takeda Pharma
  • Theravance Biopharma
  • Wockhardt

Market driver

  • Special regulatory designation for pipeline molecules
  • For a full, detailed list, view our report

Market challenge

  • Development of drug resistance
  • For a full, detailed list, view our report

Market trend

  • Use of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Cephalosporin overview

  • Introduction
  • Precursors of cephalosporins
  • Mechanism of action
  • General principles for use of antibiotics
  • Clinical uses
  • Epidemiology

PART 06: Overview on the consumption of antibiotics

  • Latin America
  • Europe
  • APAC

PART 07: Legislation relating to antibiotic use in the US

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by generation of cephalosporin

  • First-generation cephalosporins
  • Second-generation cephalosporins
  • Third-generation cephalosporins
  • Fourth-generation cephalosporins
  • Fifth-generation cephalosporins

PART 10: Market segmentation by route of administration

  • Injection
  • Oral

PART 11: Geographical segmentation

  • Segmentation of global cephalosporin drugs market by geography
  • Cephalosporin drugs market in Americas
  • Cephalosporin drugs market in EMEA
  • Cephalosporin drugs market in APAC

PART 12: Market drivers

  • Special regulatory designation for pipeline molecules
  • Rise in prevalence of infectious diseases
  • Increase in awareness

PART 13: Impact of drivers

PART 14: Market challenges

  • Development of drug resistance
  • High generic penetration
  • Weak pipeline

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Use of combination therapies
  • Increase in M&A
  • Increasing irrational use of cephalosporins

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Evolution of cephalosporin drugs
  • Exhibit 03: Overview of the activity of different generations of cephalosporin drugs
  • Exhibit 04: General principles involved in use of antibiotics
  • Exhibit 05: Estimated number of cases for nosocomial infections in the US 2011
  • Exhibit 06: Number of cases of E.coli in the UK 2012-2014
  • Exhibit 07: Legislation relating to the use of antibiotics in the US
  • Exhibit 08: Global cephalosporin drugs market 2014-2019 ($ millions)
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global cephalosporin drugs market segment by generation
  • Exhibit 11: Overview of activity of different generations of cephalosporins
  • Exhibit 12: Evolution of different generations of cephalosporin drugs
  • Exhibit 13: Global cephalosporin drugs market segment by route of administration
  • Exhibit 14: Different generations of cephalosporin drugs by route of administration
  • Exhibit 15: Global cephalosporin drugs market segment by geography 2014
  • Exhibit 16: Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
  • Exhibit 17: Cephalosporin drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 18: Percentage share of cephalosporin market in Americas
  • Exhibit 19: Percentage share of market by generation of cephalosporin in the US based on revenue 2014
  • Exhibit 20: Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 21: Percentage share of cephalosporin drugs market in EMEA
  • Exhibit 22: Percentage share of market by generation of cephalosporin in EU based on revenue 2014
  • Exhibit 23: Cephalosporin drugs market in APAC 2014-2019 ($ millions)
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Cephalosporin resistant strains according to the period of development of resistance
  • Exhibit 26: Impact of drivers and challenges
  • Exhibit 27: Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
  • Exhibit 28: Allergan: Key takeaways
  • Exhibit 29: Astellas: Key takeaways
  • Exhibit 30: Bristol-Myers Squibb: Key takeaways
  • Exhibit 31: GSK: Key takeaways
  • Exhibit 32: Merck: Key takeaways
  • Exhibit 33: Pfizer: Key takeaways
  • Exhibit 34: Sandoz: Key takeaways
  • Exhibit 35: Teva Pharmaceuticals: Key takeaways
  • Exhibit 36: Allergan: Business segmentation by product revenue 2014
  • Exhibit 37: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 38: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 39: Astellas: Product segmentation by revenue 2015
  • Exhibit 40: Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
  • Exhibit 41: Astellas: Geographical segmentation by revenue 2015
  • Exhibit 42: Bristol-Myers Squibb: Segmentation by revenue 2014
  • Exhibit 43: Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 44: Bristol-Myers Squibb: Geographical segmentation by revenue 2014
  • Exhibit 45: GSK: Business segmentation by revenue 2014
  • Exhibit 46: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 47: GSK: Geographical segmentation by revenue 2014
  • Exhibit 48: Merck: Business segmentation by revenue 2014
  • Exhibit 49: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 50: Merck: Geographical segmentation by revenue 2014
  • Exhibit 51: Pfizer: Business segmentation by revenue 2014
  • Exhibit 52: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 53: Pfizer: Geographical segmentation by revenue 2014
  • Exhibit 54: Sandoz: Business segmentation by revenue 2014
  • Exhibit 55: Teva Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 56: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
  • Exhibit 57: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
Back to Top